Home LiteratureArticle Details
PMID: 19425057 Published · ppublish English Journal Article Research Support, N.I.H., Intramural Review

The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

Movement disorders : official journal of the Movement Disorder Society ·Vol. 24 ·No. 11 ·2009-08-15 ·Pages 1571-8

DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E

Abstract

A body of work has emerged over the past decade demonstrating a relationship between mutations in glucocerebrosidase gene (GBA), the gene implicated in Gaucher disease (GD), and the development of parkinsonism. Several different lines of research support this relationship. First, patients with GD who are homozygous for mutations in GBA have a higher than expected propensity to develop Parkinson's disease (PD). Furthermore, carriers of GBA mutations, particularly family members of patients with GD, have displayed an increased rate of parkinsonism. Subsequently, investigators from centers around the world screened cohorts of patients with parkinsonism for GBA mutations and found that overall, subjects with PD, as well as other Lewy body disorders, have at least a fivefold increase in the number of carriers of GBA mutations as compared to age-matched controls. In addition, neuropathologic studies of subjects with parkinsonism carrying GBA mutations demonstrate Lewy bodies, depletion of neurons of the substantia nigra, and involvement of hippocampal layers CA2-4. Although the basis for this association has yet to be elucidated, evidence continues to support the role of GBA as a PD risk factor across different centers, synucleinopathies, and ethnicities. Further studies of the association between GD and parkinsonism will stimulate new insights into the pathophysiology of the two disorders and will prove crucial for both genetic counseling of patients and family members and the design of relevant therapeutic strategies for specific patients with parkinsonism.

MeSH Terms
Adult Aged Child DNA Mutational Analysis Enzyme Replacement Therapy Ethnicity/genetics Female Gaucher Disease/drug therapy,epidemiology,genetics,pathology Genetic Counseling Genetic Predisposition to Disease Glucosylceramidase/genetics,therapeutic use Hippocampus/pathology Humans Lewy Body Disease/epidemiology,genetics Lysosomes/enzymology Male Middle Aged Mutation Parkinsonian Disorders/enzymology,epidemiology,genetics,pathology Risk Factors Substantia Nigra/pathology alpha-Synuclein/genetics,metabolism
Chemicals
alpha-Synuclein Glucosylceramidase
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
DePaolo John
Section on Molecular Neurogenetics, Medical Genetics Branch, NHGRI, National Institutes of Health, Bethesda, Maryland 20892-3708, USA.
Goker-Alpan Ozlem
Samaddar Ted
Lopez Grisel
Sidransky Ellen
References (50)
50 references, click to expand
  1. The relationship between Lewy body disease, Parkinson's disease, and Alzheimer's disease.
    Ann N Y Acad Sci. 2003 Jun;991:167-70 PMID: 12846985
  2. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    N Engl J Med. 2005 Feb 17;352(7):728-31; author reply 728-31 PMID: 15716572
  3. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.
    Arch Neurol. 2008 Mar;65(3):379-82 PMID: 18332251
  4. Occurrence of Parkinson's syndrome in type I Gaucher disease.
    QJM. 1996 Sep;89(9):691-4 PMID: 8917744
  5. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.
    Blood Cells Mol Dis. 2006 May-Jun;36(3):426-8 PMID: 16651014
  6. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.
    Mov Disord. 2005 Jan;20(1):100-3 PMID: 15517591
  7. Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease.
    FEBS J. 2008 Dec;275(23):5767-73 PMID: 19021754
  8. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
    Chem Biol. 2005 Nov;12(11):1235-44 PMID: 16298303
  9. alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons.
    J Biol Chem. 2004 Nov 5;279(45):46915-20 PMID: 15322100
  10. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
    Science. 2004 Aug 27;305(5688):1292-5 PMID: 15333840
  11. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  12. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese.
    J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):977-9 PMID: 17702778
  13. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
    Neurology. 2008 Jun 10;70(24):2277-83 PMID: 18434642
  14. Olfactory Receptor Database: a metadata-driven automated population from sources of gene and protein sequences.
    Nucleic Acids Res. 2002 Jan 1;30(1):354-60 PMID: 11752336
  15. Type 2 and type 3 Gaucher disease: a morphological and biochemical study.
    Ann Neurol. 1986 Aug;20(2):223-30 PMID: 3752966
  16. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.
    Arch Intern Med. 2000 Oct 9;160(18):2835-43 PMID: 11025794
  17. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.
    Neurology. 2006 Sep 12;67(5):908-10 PMID: 16790605
  18. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies.
    J Neuropathol Exp Neurol. 2003 Apr;62(4):389-97 PMID: 12722831
  19. Accelerated alpha-synuclein fibrillation in crowded milieu.
    FEBS Lett. 2002 Mar 27;515(1-3):99-103 PMID: 11943202
  20. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population.
    Neurology. 2006 Feb 14;66(3):415-7 PMID: 16476943
  21. Glucocerebrosidase mutations in subjects with parkinsonism.
    Mol Genet Metab. 2004 Jan;81(1):70-3 PMID: 14728994
  22. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
    Mol Genet Metab. 2003 Jun;79(2):104-9 PMID: 12809640
  23. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
    Cell Death Differ. 1998 Oct;5(10):832-7 PMID: 10203692
  24. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.
    Mol Genet Metab. 2007 Jun;91(2):195-200 PMID: 17462935
  25. [Neurological manifestations in patients with Gaucher disease and in their relatives].
    Med Clin (Barc). 2008 Jul 5;131(5):175-9 PMID: 18674488
  26. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.
    Neurology. 2007 Sep 18;69(12):1270-7 PMID: 17875915
  27. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela.
    Mov Disord. 2006 Feb;21(2):282-3 PMID: 16261622
  28. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization.
    Mol Genet Metab. 2001 Aug;73(4):313-21 PMID: 11509013
  29. Parkinsonism among Gaucher disease carriers.
    J Med Genet. 2004 Dec;41(12):937-40 PMID: 15591280
  30. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation.
    Neurology. 2005 Nov 8;65(9):1460-1 PMID: 16148263
  31. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    N Engl J Med. 2004 Nov 4;351(19):1972-7 PMID: 15525722
  32. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal.
    Neurobiol Aging. 2009 Sep;30(9):1515-7 PMID: 18160183
  33. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease.
    Am J Hematol. 1999 Jul;61(3):216-7 PMID: 10398575
  34. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    N Engl J Med. 2005 Feb 17;352(7):728-31; author reply 728-31 PMID: 15719451
  35. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
    Neuron. 2002 Dec 19;36(6):1007-19 PMID: 12495618
  36. Analysis of the glucocerebrosidase gene in Parkinson's disease.
    Mov Disord. 2005 Mar;20(3):367-70 PMID: 15517592
  37. Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients.
    Arch Neurol. 2007 Jul;64(7):1056-8 PMID: 17620502
  38. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations.
    Arch Neurol. 2008 Oct;65(10):1353-7 PMID: 18852351
  39. Gaucher disease: complexity in a "simple" disorder.
    Mol Genet Metab. 2004 Sep-Oct;83(1-2):6-15 PMID: 15464415
  40. The pathology of Gaucher disease.
    Prog Clin Biol Res. 1982;95:177-217 PMID: 7122634
  41. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
    Biochemistry. 2002 Apr 9;41(14):4595-602 PMID: 11926821
  42. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    J Mol Biol. 2002 Oct 4;322(5):1089-102 PMID: 12367530
  43. Association between Parkinson's disease and glucocerebrosidase mutations in Brazil.
    Parkinsonism Relat Disord. 2008;14(1):58-62 PMID: 17703984
  44. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
    J Biol Chem. 2002 Feb 22;277(8):6344-52 PMID: 11744721
  45. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation.
    Mov Disord. 2001 Nov;16(6):1007-13 PMID: 11748731
  46. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy.
    Mov Disord. 2008 Feb 15;23(3):460-3 PMID: 18074383
  47. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).
    Hum Mutat. 2008 May;29(5):567-83 PMID: 18338393
  48. Neuropathology provides clues to the pathophysiology of Gaucher disease.
    Mol Genet Metab. 2004 Jul;82(3):192-207 PMID: 15234332
  49. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset.
    Neurology. 2009 Jan 27;72(4):310-6 PMID: 18987351
  50. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.
    Brain. 2005 Dec;128(Pt 12):2786-96 PMID: 16272164
Article Info
Journal
Movement disorders : official journal of the Movement Disorder Society
Abbr.
Mov Disord
ISSN
1531-8257
Published
2009-08-15
Pages
1571-8
Language
English
Region
United States
NLM ID
8610688
PMCID
PMC2736332
Subset
IM
Grants
Intramural NIH HHS · Z01 HG200336-02 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]